Tuberc Respir Dis.  2006 Mar;60(3):270-276.

The Up-to-date of Anti-Tuberculosis Treatment

• Lew WJ

Abstract

No abstract available.

Reference

1. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med. 2001. 163:1055–1058.

2. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998. 393:537–544.

3. Telenti A. Iseman MD, Huitt GA, editors. Genetics of drug resistance in tuberculosis. Clinics in chest medicine. 1997. Philadelphia: WB Saunders;55–64.

4. Lew WJ, Park YK, Kim HJ, Chang CH, Bai GH, Kim SK. The proportion of rifabutin-susceptible strains among rifampicin-resistant isolates and its specific rpoB mutations. Tuberc Respir Dis. 2005. 59(3):257–265.

5. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med. 2003. 167:603–662.

6. Joia SM, Michael LR, Adrienne RS, Keith JJ, Felix AV, Sonya SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 2004. 363:474–481.

7. Tuberculosis Research Centre. Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Ind J Tub. 2002. 49:27–38.

8. Cambau E, Jarlier V. Resistance to quinolones in mycobacteria. Res Microbiol. 1996. 147:52–59.

9. Gosling RD, Uiso LO, Sam NE, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 2003. 168:1342–1345.

10. Sterling T.R. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis. 2004. 8(12):1396–1400.

11. Shim TS. Seoul Asan Medical Center. (personal communication).

12. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000. 405:962–966.

13. Iseman MD, editor. Chapter 13. Vaccination to prevent tuberculosis and immunomodulatory therapy for persons with active disease. A Clinician's guide to tuberculosis. 2000. Lippincott Williams & Wilkins;417–425.

14. Han SK. The up-to-date of tuberculosis treatment. The annual course for respiratology. 2002. In : Hanyang Medical School;

15. Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous Interferon-gamma in the treatment of refractory multidrug-resistant pulmonary tuberculosis. Tuberc Respir Dis. 2004. 57:226–233.

16. Park SK, Jun DS, Lee YH, Lee DH. Treatment of multidrug-resistant pulmonary tuberculosis with Interferon-gamma subcutaneous injection. Tuberc Respir Dis. 2003. 55:Suppl 2. 84.

17. Koh WJ, Ahn CH, Kim CH, Ahn YM, Lim SY, Seo JY. The therapeutic effect of 6-month inhaled Interferon-gamma treatment in intractible multi-drug resisdtant pulmonary tuberculosis. Tuberc Respir Dis. 2001. 51:Suppl 2. 116.

18. Giosue S, Casarini M, Alemanno L, et al. Effects of aerosolized interferon-αin patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1998. 158:1156–1162.

19. Onyebujoh PC, Levin JB, Fourie PB, et al. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet. 1999. 354:116–119.

20. Jane MT, Utaiwan U, Anthomy M, Pasakorn A, Margaret B, Sanit M, et al. Thalidomide treatment reduces TNF-α production and enhances weight gain in patients with pulmonary tuberculosis. Molecular Medicine. 1995. 1(4):384–397.

21. Wallis RS, Nsubuga P, Whalen C, Mugerwa RD. Pentoxifylline therapy in HIV-seropositive persons with tuberculosis: a randomized, controlled trial. J Inf Dis. 1996. 174:727–733.

22. Ha SJ, Jeon BY, Youn JI, Kim SC, Cho SN, Sung YC. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Therapy. 2005. 1–5.

23. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDA major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci. 2000. 97:13853–13858.

24. Rieder Hans L. Interventions for tuberculosis control and elimination. IUATLD. 2002. 153–169.

25. Cynamon Michael H. Friedman Lloyd N, editor. Chemotherapeutic agents for Mycobacterial infections. Tuberculosis: current concepts and treatment. 2001. 2nd edition. CRC Press;301–332.